Experience

ALVA10

• United States
• Biotechnology Research
• 1 - 100 Employee

• Founder and CEO

  • Mar 2016 - Present

  Cambridge, MA I am passionate about precision medicine, and using technology to best treat patients and lower healthcare costs. Right now, as a healthcare society, we are failing at this. At Alva10, we are changing market dynamics to pull new diagnostic and device tools into the healthcare system. Our model is based on the fact that the realization of precision medicine will require that big data be translated into well validated, broadly distributed diagnostics that are valued (paid for)… Show more I am passionate about precision medicine, and using technology to best treat patients and lower healthcare costs. Right now, as a healthcare society, we are failing at this. At Alva10, we are changing market dynamics to pull new diagnostic and device tools into the healthcare system. Our model is based on the fact that the realization of precision medicine will require that big data be translated into well validated, broadly distributed diagnostics that are valued (paid for) within the healthcare system. Alva10 was founded to drive an increase in value in diagnostics and device technology in healthcare, creating a mechanism to fund innovation and increase reimbursement. To do this, we create partnerships between payers and diagnostic companies, to align incentives and economics for both parties, and most importantly, to improve patient outcomes. Show less



Chief

• United States
• Think Tanks
• 700 & Above Employee

• Founding Member

  • Dec 2020 - Present



Carolina Health Informatics Program

• United States
• Education Management
• 1 - 100 Employee

• Advisory Board Member

  • Jan 2021 - Present

  Chapel Hill, North Carolina, United States



Bionano

• United States
• Biotechnology Research
• 200 - 300 Employee

• Board Member

  • May 2020 - Present

  San Diego, California, United States



Circle Cardiovascular Imaging

• Canada
• Software Development
• 100 - 200 Employee

• Board Member

  • May 2021 - Jul 2022

  Circle Cardiovascular was acquired by Thoma Bravo.



Exosome Diagnostics

• United States
• Biotechnology Research
• 1 - 100 Employee

• VP of Business Development

  • 2010 - 2015

  Cambridge, MA Exosome Diagnostics was founded based on a significant discovery made in 2008 at Massachusetts General Hospital in Boston, which demonstrated that exosomes, which contain all manner of nucleic acids, including RNA, could be stably isolated from biofluids. In my 5 years at Exosome Dx, I completed several milestone transactions which allowed the company to go from nascent startup up to commercial stage company, including: -Multiple deals with global pharmaceutical companies -Multiple… Show more Exosome Diagnostics was founded based on a significant discovery made in 2008 at Massachusetts General Hospital in Boston, which demonstrated that exosomes, which contain all manner of nucleic acids, including RNA, could be stably isolated from biofluids. In my 5 years at Exosome Dx, I completed several milestone transactions which allowed the company to go from nascent startup up to commercial stage company, including: -Multiple deals with global pharmaceutical companies -Multiple deals with global IVD manufacturers -Introduction of new technology to molecular diagnostic market Show less



Exiqon

• Global Director of Pharmaceutical Alliances

  • Dec 2004 - Jan 2010

  During my time at Oncotech and later Exiqon (after Exiqon acquired Oncotech), I initiated and managed more than 100 projects with external pharmaceutical clients, ranging from smaller biotech/pharma companies to large global pharmaceutical companies. Our focus was to work with our clients to determine the MOA of novel compoounds; determine which pathways are most important for their activity; and to work together to develop and validate biomarkers, both preclinically and clinically, which… Show more During my time at Oncotech and later Exiqon (after Exiqon acquired Oncotech), I initiated and managed more than 100 projects with external pharmaceutical clients, ranging from smaller biotech/pharma companies to large global pharmaceutical companies. Our focus was to work with our clients to determine the MOA of novel compoounds; determine which pathways are most important for their activity; and to work together to develop and validate biomarkers, both preclinically and clinically, which advance the development of the drug. -Responsible for global Pharmaceutical Services group, overseeing clinical project management in three sites -Managed cross-functional team, coordinated projects between labs, managed data analysis and reports, presented data to pharmaceutical clients -Responsible for development and implemenation of company pharmaceutical services strategy -Oversaw yearly +100% year-over-year growth for four years, consistently exceeding revenue goals -Identified intellectual property related to diagnostic markers paired with novel targeted therapies for oncology Show less



Asuragen

• United States
• Biotechnology
• 100 - 200 Employee

• Strategic Business Development, Companion Diagnostics

  • 2010 - 2010

  Austin, Texas Area Asuragen provides pharmacogenomic services as well as companion diagnostic development support to pharmaceutical clients. In my role, I reformatted Asuragen's approach to pharma clients, focusing on pharma client clinical trial and commercial needs and leveraging Asuragen's technical portfolio.



Oncotech, Inc.

• Biotechnology Research
• 1 - 100 Employee

• Director of Pharmaceutical Alliances

  • 2004 - 2010

  During my time at Oncotech and later Exiqon (after Exiqon acquired Oncotech), I initiated and managed more than 100 projects with external pharmaceutical clients, ranging from smaller biotech/pharma companies to large global pharmaceutical companies. Our focus was to work with our clients to determine the MOA of novel compounds; determine which pathways are most important for their activity; and to work together to develop and validate biomarkers, both preclinically and clinically, which… Show more During my time at Oncotech and later Exiqon (after Exiqon acquired Oncotech), I initiated and managed more than 100 projects with external pharmaceutical clients, ranging from smaller biotech/pharma companies to large global pharmaceutical companies. Our focus was to work with our clients to determine the MOA of novel compounds; determine which pathways are most important for their activity; and to work together to develop and validate biomarkers, both preclinically and clinically, which advance the development of the drug. -Responsible for global Pharmaceutical Services group, overseeing clinical project management in three sites -Managed cross-functional team, coordinated projects between labs, managed data analysis and reports, presented data to pharmaceutical clients -Responsible for development and implemenation of company pharmaceutical services strategy -Oversaw yearly +100% year-over-year growth for four years, consistently exceeding revenue goals -Identified intellectual property related to diagnostic markers paired with novel targeted therapies for oncology Show less



ArQule

• Scientist

  • 2003 - 2004

  Cell and molecular biology development work for preclinical compounds.



Takeda Oncology

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Research Associate

  • 1999 - 2003

  Cambridge, MA Cell and molecular biology development including work on the NDA for Velcade, the first proteasome inhibitor approved for clinical use.



Organogenesis

• Biotechnology Research
• 700 & Above Employee

• Research Associate

  • 1998 - 1999

  Cell biologist and tissue culture specialist